Explore opportunities
Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.
Loading filters…
Cortical allograft kyphoplasty without PMMA—commercial early with Series A traction.
NEMIC + Commerce voucher—growth equity, not university OTL formation.
Open dossierDeepest RI immunoinformatics patent cluster—platform ARR plus therapeutic spinouts.
Growth/strategic capital on Tregitope stack—not classic Slater seed formation.
Open dossierBRF biglycan MSK regeneration—classic Brown OTL out-license with no RI startup mapped.
Preclinical academic package—physician KOL SAB + Slater seed after PoC.
Foundational BMI decode patents—FTO diligence essential for new neurotech entrants.
Royalty or field-of-use license vs wireless/speech sub-families.
Open dossierFDA-cleared AI AF ablation mapping—growth-stage SaMD with protected claims.
~€74M VC path—strategic or growth round, not formation.
Open dossierSee malignant margins and treat in the same OR workflow—AI-guided optical theranostics.
RILSH attraction award + Ocean State Labs + Mayo know-how—medtech growth, not university OTL.
Open dossierKIWI wireless micro-implant BCI—Providence HQ with BrainGate FTO diligence.
Nurosene partnership + strategic path—harvest Howard/ni2o USPTO vs Brown patents.
Open dossierHIF-pathway oncology with Welireg-scale commercial proof—harvest El-Deiry estate.
R01CA173453 + SMURF-Tx Providence—Slater seed after biomarker PoC.
Open dossierCOBRE-backed interoception pain DTx—spinout forming from Carney.
Kaia-class financing vs Pear Ch.11 payer lesson—SaMD path after pivotal pilot.
HiTIMED immune epigenetic deconvolution—Dartmouth EP pending, Brown collaborator.
R01 stack + EP4505463A1—pharma license model, not classic biotech VC.
Wearable ML for earlier pediatric sepsis recognition—validated in Bangladesh ICU cohort.
FIC R33TW012211 → US SaMD path; pairs with RIH RNA Dx stack.
URI PHLIP delivers cargo into acidic tissues—LNP and STING programs without classic endocytosis.
URI tech transfer → RI spinout or license; Engelman/Reshetnyak PHLIP science (PMID 24659971).
Salivary extracellular vesicles as a non-invasive Alzheimer's liquid biopsy.
RIH/Brown R01AG074284 supports analytical development; path to CLIA LDT then spinout.
BX-912 program for pulmonary hypertension—RIH PCT with multi-center inventor team.
Preclinical PH models → IND-enabling; benchmark against 2024 PAH biologic approval.
RIH diagnostic panel for pulmonary arterial hypertension and sudden cardiac death risk.
Mature US20180094317 family; retrospective → prospective validation.
RIH platform for nucleic acid delivery across the blood–brain barrier.
Qian Chen (NanoDe peer) leads BBB nucleic delivery PCT; partner or license path.
Motile injectable cell therapy to accelerate meniscus and connective-tissue repair.
NIAMS R01AR080726 + R21AR077326 (Jayasuriya); large-animal next gate.
Biomimetic ECM reconstitution for musculoskeletal joint repair.
Field-of-use diligence vs XM Therapeutics before Slater-scale spinout.
Enhancer RNA–targeted approach for primary brain tumors.
Tapinos-led RIH/Brown program; glioma model efficacy before neuro-onc seed.
RIH therapeutic approach to lower lipoprotein(a)—cardiovascular metabolic niche.
Differentiate vs Phase 3 siRNA/antisense leaders; Song lab R01HL159204 anchors cardio lipid biology.